Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Issue 7 (2nd July 2016)

• Record Type: Journal Article
• Authors: Hudspeth, Elissa M.; Wang, Qian; Seid, Christopher A.; Hammond, Molly; Wei, Junfei; Liu, Zhuyun; Zhan, Bin; Pollet, Jeroen; Heffernan, Michael J.; McAtee, C. Patrick; Engler, David A.; Matsunami, Risë K.; Strych, Ulrich; Asojo, Oluwatoyin A.; Hotez, Peter J.; Bottazzi, Maria Elena
• Is Part Of: Human vaccines & immunotherapeutics. Volume 12:Issue 7(2016)
• Page Start: 1707
• Page End: 1720
• Publication Date: 2016-07-02
• Subjects: CpG Oligodeoxynucleotide -- fermentation -- Leishmania donovani -- Poly(lactic-co-glycolic acid) (PLGA) -- purification; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2016.1139254
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Leishmania donovani is the major cause of visceral leishmaniasis (kala-azar), now recognized as the parasitic disease with the highest level of mortality second only to malaria. No human vaccine is currently available. A 36 kDa L. donovani nucleoside hydrolase (LdNH36) surface protein has been previously identified as a potential vaccine candidate antigen. Here we present data on the expression of LdNH36 in Pichia pastoris and its purification at the 20 L scale to establish suitability for future pilot scale manufacturing. To improve efficiency of process development and ensure reproducibility, 4 N-linked glycosylation sites shown to contribute to heterogeneous high-mannose glycosylation were mutated to glutamine residues. The mutant LdNH36 (LdNH36-dg2) was expressed and purified to homogeneity. Size exclusion chromatography and light scattering demonstrated that LdNH36-dg2 existed as a tetramer in solution, similar to the wild-type recombinant L. major nucleoside hydrolase. The amino acid mutations do not affect the tetrameric interface as confirmed by theoretical modeling, and the mutated amino acids are located outside the major immunogenic domain. Immunogenic properties of the LdNH36-dg2 recombinant protein were evaluated in BALB/c mice using formulations that included a synthetic CpG oligodeoxynucleotide, together with a microparticle delivery platform (poly(lactic-co-glycolic acid)). Mice exhibited high levels of IgG1, IgG2a, and IgG2b antibodies that were reactive to both LdNH36-dg2 and LdNH36 wild-type. While the point mutations did affect the hydrolase activity of the enzyme, the IgG antibodies elicited by LdNH36-dg2 were shown to inhibit the hydrolase activity of the wild-type LdNH36. The results indicate that LdNH36-dg2 as expressed in and purified from P. pastoris is suitable for further scale-up, manufacturing, and testing in support of future first-in-humans phase 1 clinical trials.